BRD4 and acute myeloid leukemia: For example, in acute myeloid leukemia (AML), intrinsic resistance to BET inhibition results in activation of a c-MYC enhancer that compensates for the loss of BRD4 by utilizing WNT signaling to drive oncogenesis28.